Are all antihypertensive drug classes equal in reducing left ventricular hypertrophyß

被引：23

作者：

Fleischmann E.H. ^{[1
]}

Schmieder R.E. ^{[1
]}

机构：

[1] Department of Internal Medicine 4/IV, University of Erlangen- Nuremberg, 90475 Nuremberg

来源：

Current Cardiology Reports | 2002年 / 4卷 / 6期

关键词：

Left Ventricular Hypertrophy; Losartan; Left Ventricular Mass; Irbesartan; Leave Ventricular Mass Index;

D O I：

10.1007/s11886-002-0109-2

中图分类号：

学科分类号：

摘要：

Left ventricular hypertrophy (LVH) is a major cardiovascular risk factor for morbidity and mortality. It is caused by arterial hypertension, although various hemodynamic and nonhemodynamic factors contribute to its development. Especially, the renin-angiotensin-aldosterone system is involved in the pathophysiology of LVH. The Treatment of Mild Hypertension study demonstrated that in mild essential hypertension, nonpharmacologic treatment is an effective tool for treating LVH. There are at least three major meta-analyses with several thousand patients examining the ability of antihypertensive drugs on the reversal of LVH. The results of these meta-analyses are very consistent. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers achieve significantly better results than ß-blockers. The most recently published Losartan Intervention For Endpoint reduction in hypertension study confirmed the superiority of angiotensin receptor blockers against ß-blockers in a large-scale prospective trial. It also proves for the first time that regression of LVH is associated with better cardiovascular outcome. Copyright © 2002 by Current Science Inc.

引用

页码：474 / 478

页数：4

共 33 条

[1]

Savage D.D., Levy D., Dannenberg A.L., Et al., Association of echocardiographic left ventricular mass with body size, blood pressure and physical activity (the framingham study), Am J Cardiol, 65, pp. 371-376, (1990)

[2]

Levy D., Anderson K.M., Savage D.D., Et al., Echocardiographically detected left ventricular hypertrophy: Prevalence and risk factors. The framingham heart study, Ann Intern Med, 108, pp. 7-13, (1988)

[3]

Ghali J.K., Liao Y., Simmons B., Et al., The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease, Ann Intern Med, 117, pp. 831-836, (1992)

[4]

Koren M.J., Devereux R.B., Casale P.N., Et al., Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension, Ann Intern Med, 114, pp. 345-352, (1991)

[5]

Levy D., Garrison R.J., Savage D.D., Et al., Prognostic implications of echocardiographically determined left ventricular mass in the framingham heart study, N Engl J Med, 322, pp. 1561-1566, (1990)

[6]

Devereux R.B., Reichek N., Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method, Circulation, 55, pp. 613-618, (1977)

[7]

Devereux R.B., Lutas E.M., Casale P.N., Et al., Standardization of m-mode echocardiographic left ventricular anatomic measurements, J Am Coll Cardiol, 4, pp. 1222-1230, (1984)

[8]

Dahlof B., Devereux R., De Faire U., Et al., The losartan intervention for endpoint reduction (life) in hypertension study: Rationale, design, and methods. The life study group, Am J Hypertens, 10, pp. 705-713, (1997)

[9]

White W.B., Schulman P., McCabe E.J., Dey H.M., Average daily blood pressure, not office blood pressure, determines cardiac function in patients with hypertension, JAMA, 261, pp. 873-877, (1989)

[10]

Verdecchia P., Schillaci G., Guerrieri M., Et al., Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension, Circulation, 81, pp. 528-536, (1990)

← 1 2 3 4 →